october, 2017

17oct1:00 PMCAP TODAY Webinar: Introduction to PD-L1 interpretationin gastric or gastroesphageal junction adenocarcinomaEvent Type:WEBINARS

Start Time

(Tuesday) 1:00 PM

Event Details

Tuesday, October 17, 2017, 1pm–2pm EDT


Annika Eklund, PhD, Global Product Manager, Companion Diagnostics at Agilent Technologies PhD Pharmacology, Linköping University, Sweden, 2001 MSc Molecular Biology, Umeå University, Sweden, 1995 (left)
Debra Hanks, MD, Chief Pathologist, Companion Diagnostics Histopathology Department, Agilent Diagnostics and Genomics Division. US Board certified in Anatomic, Clinical, and Hematopathology. MD, University of California, San Francisco. BS, Medical Microbiology, Stanford University

Why should you register now for this webinar?

  • FDA recently approved the use of Dako PD-L1 IHC 22C3 pharmDx as an aid in identifying gastric or gastroesophageal (GEJ) adenocarcinoma patients for treatment with KEYTRUDA® (pembrolizumab).
  • A new scoring method, Combined Positive Score, is introduced for testing in gastric or GEJ adenocarcinoma.
  • Learn about the FDA approval, background for PD-L1 testing in gastric or GEJ adenocarcinoma, and CPS scoring method.
  • Ask your questions of our distinguished presenters.

Register now FREE of charge.

[hr]CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a promotional sponsorship from Agilent Technologies.